189 related articles for article (PubMed ID: 7729921)
21. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
22. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
[TBL] [Abstract][Full Text] [Related]
23. The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes.
Soto M; Alonso C; Requena JM
Clin Exp Immunol; 2000 Nov; 122(2):212-8. PubMed ID: 11091277
[TBL] [Abstract][Full Text] [Related]
24. Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi.
Leal JM; Mosquini M; Covre LP; Stagmiller NP; Rodrigues RR; Christensen D; de Matos Guedes HL; Rossi-Bergmann B; Gomes DC
Parasitology; 2015 Nov; 142(13):1640-6. PubMed ID: 26394776
[TBL] [Abstract][Full Text] [Related]
25. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
[TBL] [Abstract][Full Text] [Related]
26. Characterization of T cell responses to purified leishmania antigens in subjects infected with Leishmania chagasi.
Vinhas V; Freire M; Bacellar O; Cunha S; Rocha H; Carvalho EM
Braz J Med Biol Res; 1994 May; 27(5):1199-205. PubMed ID: 8000341
[TBL] [Abstract][Full Text] [Related]
27. Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages.
Campos-Neto A; Soong L; Cordova JL; Sant'Angelo D; Skeiky YA; Ruddle NH; Reed SG; Janeway C; McMahon-Pratt D
J Exp Med; 1995 Nov; 182(5):1423-33. PubMed ID: 7595213
[TBL] [Abstract][Full Text] [Related]
28. The importance of TGF-beta in murine visceral leishmaniasis.
Wilson ME; Young BM; Davidson BL; Mente KA; McGowan SE
J Immunol; 1998 Dec; 161(11):6148-55. PubMed ID: 9834100
[TBL] [Abstract][Full Text] [Related]
29. T cell response of asymptomatic Leishmania chagasi infected subjects to recombinant leishmania antigens.
Costa SR; D'Oliveira A; Bacellar O; Carvalho EM
Mem Inst Oswaldo Cruz; 1999; 94(3):367-70. PubMed ID: 10348984
[TBL] [Abstract][Full Text] [Related]
30. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
31. Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis.
Martins VT; Chávez-Fumagalli MA; Lage DP; Duarte MC; Garde E; Costa LE; da Silva VG; Oliveira JS; Magalhães-Soares DF; Teixeira SM; Fernandes AP; Soto M; Tavares CA; Coelho EA
PLoS One; 2015; 10(9):e0137683. PubMed ID: 26367128
[TBL] [Abstract][Full Text] [Related]
32. Small Myristoylated Protein-3, Identified as a Potential Virulence Factor in Leishmania amazonensis, Proves to be a Protective Antigen against Visceral Leishmaniasis.
Oliveira MP; Martins VT; Santos TTO; Lage DP; Ramos FF; Salles BCS; Costa LE; Dias DS; Ribeiro PAF; Schneider MS; Machado-de-Ávila RA; Teixeira AL; Coelho EAF; Chávez-Fumagalli MA
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301342
[TBL] [Abstract][Full Text] [Related]
33. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.
Ghosh A; Zhang WW; Matlashewski G
Vaccine; 2001 Oct; 20(1-2):59-66. PubMed ID: 11567746
[TBL] [Abstract][Full Text] [Related]
34. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
35. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.
Resende DM; Caetano BC; Dutra MS; Penido ML; Abrantes CF; Verly RM; Resende JM; Piló-Veloso D; Rezende SA; Bruna-Romero O; Fernandes AP; Gazzinelli RT
Vaccine; 2008 Aug; 26(35):4585-93. PubMed ID: 18588933
[TBL] [Abstract][Full Text] [Related]
36. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
Sukumaran B; Tewary P; Saxena S; Madhubala R
Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
[TBL] [Abstract][Full Text] [Related]
38. Early in vitro priming of distinct T(h) cell subsets determines polarized growth of visceralizing Leishmania in macrophages.
Gomes NA; Barreto-de-Souza V; DosReis GA
Int Immunol; 2000 Sep; 12(9):1227-33. PubMed ID: 10967017
[TBL] [Abstract][Full Text] [Related]
39. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
40. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
